2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2176

The Association of Gout with Incident Giant Cell Arteritis in Older Adults
Abstract Number: 1358

The Association of Microbial Translocation and WOMAC Function in Patients with Knee Osteoarthritis
Abstract Number: 1146

The Association of Raas Inhibitor Use with Osteoporosis. Findings from the Women’s Health Initiative
Abstract Number: 482

The Association of Short-Term Ultraviolet Radiation Exposure and Calcinosis in Juvenile Dermatomyositis in the Childhood Arthritis & Rheumatology Research Alliance Registry
Abstract Number: 2498

The Association of Vitamin D with the Lipid Profile in Rheumatoid Arthritis: An Interplay Among Genetic Polymorphisms, DHCR7 Levels and Seasonality
Abstract Number: 717

The Burden of Chronic Kidney Disease in Systemic Lupus Erythematosus (SLE): A Nationwide Epidemiologic Study
Abstract Number: 721

The Burden of Renal Arteriosclerosis in Lupus Nephritis: A Cohort Study Examining Prevalence and Predictors of Renal Arteriosclerosis
Abstract Number: 840

The CCL21/CCR7 Axis Drives Vascular, Inflammatory and Destructive Remodeling in Rheumatoid Arthritis
Abstract Number: 1265

The Challenges of Managing Gout in Primary Care: Results of a Best Practice Audit
Abstract Number: 2983

The Changing Faces of Rheumatoid Arthritis Patients at Presentation: A 20-Year Study
Abstract Number: 1197

The Characteristics of the Distribution of Normal Feeding Vessels between Young and Elderly Adults in Wrist Joints of Healthy Volunteers Depicted By Ultrasound (MSKUS)
Abstract Number: 2385

The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Updated Report of Baseline Patient Characteristics and Treatment Choices
Abstract Number: 2016

The Chromatin Landscape Around the Juvenile Arthritis-Associated CXCR4 Locus Suggests Regulatory Functions and Genetic Roles in Both Innate and Adaptive Immunity
Abstract Number: 1045

The Coll2-1 Peptide of Collagen Type II: A New Actor of Synovitis in Osteoarthritis
Abstract Number: 2446

The Combined Use of Folic Acid Influenced the Time until the Development of Lymphoproliferative Disorders in Patients with Rheumatoid Arthritis during Treatment with Methotrexate

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].